195 related articles for article (PubMed ID: 27340772)
41. Clinical characteristics and treatment outcomes among respiratory syncytial virus (RSV)-infected hematologic malignancy and hematopoietic stem cell transplant recipients receiving palivizumab.
Permpalung N; Mahoney MV; McCoy C; Atsawarungruangkit A; Gold HS; Levine JD; Wong MT; LaSalvia MT; Alonso CD
Leuk Lymphoma; 2019 Jan; 60(1):85-91. PubMed ID: 29947555
[TBL] [Abstract][Full Text] [Related]
42. Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institution-specific guideline.
McCoy D; Wong E; Kuyumjian AG; Wynd MA; Sebti R; Munk GB
Transpl Infect Dis; 2011 Apr; 13(2):117-21. PubMed ID: 20804534
[TBL] [Abstract][Full Text] [Related]
43. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus.
Liu YC; Lu PL; Hsiao HH; Chang CS; Liu TC; Yang WC; Lin SF
Ann Hematol; 2012 Apr; 91(4):587-95. PubMed ID: 21997849
[TBL] [Abstract][Full Text] [Related]
44. Assessment of a cytomegalovirus serology dual-testing strategy in hematopoietic stem cell transplant recipients.
Perry DA; Hakki M
Transpl Infect Dis; 2016 Oct; 18(5):809-814. PubMed ID: 27502917
[TBL] [Abstract][Full Text] [Related]
45. [Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation].
Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Zhao XS; Yu L; Han W; Zhang XH; Wang Y; Chen Y; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):77-81. PubMed ID: 19563015
[TBL] [Abstract][Full Text] [Related]
46. Infection with novel respiratory syncytial virus genotype Ontario (ON1) in adult hematopoietic cell transplant recipients, Texas, 2011-2013.
Avadhanula V; Chemaly RF; Shah DP; Ghantoji SS; Azzi JM; Aideyan LO; Mei M; Piedra PA
J Infect Dis; 2015 Feb; 211(4):582-9. PubMed ID: 25156562
[TBL] [Abstract][Full Text] [Related]
47. Restrictive Palivizumab Use Does Not Lead to Increased Morbidity and Mortality in Pediatric Hematopoietic Stem Cell Transplantation Patients.
Teusink-Cross A; Davies SM; Danziger-Isakov L; El-Bietar J; Grimley MS
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1904-1906. PubMed ID: 27422147
[TBL] [Abstract][Full Text] [Related]
48. [Risk factors of cytomegalovirus infection and antiviral efficacy in recipients of hematopoietic stem cell transplantation].
Ding H; Ren H; Guo N; Huang X; Xu L; Zhang Y; Lu D
Beijing Da Xue Xue Bao Yi Xue Ban; 2003 Dec; 35(6):596-9. PubMed ID: 14710251
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic yield of the cytomegalovirus (CMV) antigenemia assay and clinical features in solid organ transplant recipients and hematopoietic stem cell transplant recipients with CMV pneumonia.
Moon SM; Sung H; Kim MN; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH
Transpl Infect Dis; 2012 Apr; 14(2):192-7. PubMed ID: 22260384
[TBL] [Abstract][Full Text] [Related]
50. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A;
Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
[TBL] [Abstract][Full Text] [Related]
51. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
Zikos P; Van Lint MT; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; Bacigalupo A
Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
[TBL] [Abstract][Full Text] [Related]
52. The significance of cytomegalovirus viremia at day 100 or more following allogeneic hematopoietic stem cell transplantation.
Rowe J; Grim SA; Peace D; Lai C; Sweiss K; Layden JE; Clark NM
Clin Transplant; 2013; 27(4):510-6. PubMed ID: 23621704
[TBL] [Abstract][Full Text] [Related]
53. [Clinical features of cytomegalovirus pneumonia after allogeneic hematopoietic stem cell transplantation].
Zhao XS; Liu DH; Xu LP; Chen H; Chen YH; Zhang XH; Han W; Wang Y; Liu KY; Huang XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):548-53. PubMed ID: 19829672
[TBL] [Abstract][Full Text] [Related]
54. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
[TBL] [Abstract][Full Text] [Related]
55. HLA-DRB1*09 is associated with increased incidence of cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation.
Du J; Liu J; Gu J; Zhu P
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1417-21. PubMed ID: 18022570
[TBL] [Abstract][Full Text] [Related]
56. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients.
Konoplev S; Champlin RE; Giralt S; Ueno NT; Khouri I; Raad I; Rolston K; Jacobson K; Tarrand J; Luna M; Nguyen Q; Whimbey E
Bone Marrow Transplant; 2001 Apr; 27(8):877-81. PubMed ID: 11477447
[TBL] [Abstract][Full Text] [Related]
57. The role of immunoglobulin prophylaxis for prevention of cytomegalovirus infection in pediatric hematopoietic stem cell transplantation recipients.
Goldstein G; Rutenberg TF; Mendelovich SL; Hutt D; Oikawa MT; Toren A; Bielorai B
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28087884
[TBL] [Abstract][Full Text] [Related]
58. [Respiratory syncytial virus infection in hematopoietic stem cell transplantation recipients with primary immunodeficiencies].
Liu P; Zhao Y; Xiao JW; Zhang C; Zhao XD
Zhonghua Er Ke Za Zhi; 2011 Jul; 49(7):489-94. PubMed ID: 22088176
[TBL] [Abstract][Full Text] [Related]
59. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
[TBL] [Abstract][Full Text] [Related]
60. Safety of leukoreduced, cytomegalovirus (CMV)-untested components in CMV-negative allogeneic human progenitor cell transplant recipients.
Nash T; Hoffmann S; Butch S; Davenport R; Cooling L
Transfusion; 2012 Oct; 52(10):2270-2. PubMed ID: 23110735
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
